US FDA approves Ultragenyx's gene therapy for rare disorder
17/09/2026 19:39
US FDA approves Ultragenyx's gene therapy for rare disorder Sept 17 (Reuters) - The U.S Food and Drug Administration said on Thursday it has approved Ultragenyx's RARE.O gene therapy for the treatment of a rare, fatal disease.
(Reporting by Sriparna Roy and Kamal Choudhury in Bengaluru; Editing by Maju Samuel)
Recent news on Ultragenyx Pharmaceutical
See all newsBrief: Ultragenyx Pharmaceutical Enters Settlement Agreement With Navinta On Dojolvi Patent Litigation - SEC Filing
Ultragenyx gains on $210 million US FDA voucher sale
Brief: Ultragenyx Pharmaceutical - Under Deal With U.S. Department Of Health Co To Pay 20% Of Prv Sale Proceeds To Nih
Brief: Ultragenyx Enters Into Agreement To Sell Rare Pediatric Disease Priority Review Voucher For $210 Million
U.S. STOCKS ON THE MOVE-CoreWeave, StubHub, Ultragenyx